- Cambridge MA, US John Evans - Cambridge MA, US Michael Packer - Cambridge MA, US Yanfang Fu - Cambridge MA, US Nicole Gaudelli - Cambridge MA, US Jason Michael Gehrke - Cambridge MA, US J. Keith Joung - Cambridge MA, US
Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.
Compositions And Methods For Treating Hemoglobinopathies
- Cambridge MA, US Nicole GAUDELLI - Cambridge MA, US Yi YU - Cambridge MA, US Bernd ZETSCHE - Cambridge MA, US David A. BORN - Cambridge MA, US Seung-Joo LEE - Cambridge MA, US Michael PACKER - Cambridge MA, US
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
Compositions And Methods For Treating Hemoglobinopathies
- Cambridge MA, US Nicole GAUDELLI - Cambridge MA, US Yi YU - Cambridge MA, US Bernd ZETSCHE - Cambridge MA, US David A. BORN - Cambridge MA, US Seung-Joo LEE - Cambridge MA, US Michael PACKER - Cambridge MA, US
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
Compositions And Methods For Treating Hemoglobinopathies
- Cambridge MA, US Nicole GAUDELLI - Cambridge MA, US Yi YU - Cambridge MA, US Bernd ZETSCHE - Cambridge MA, US David A. BORN - Cambridge MA, US Seung-Joo LEE - Cambridge MA, US Michael PACKER - Cambridge MA, US
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
Compositions And Methods For Treating Alpha-1 Antitrypsin Deficiency
- Cambridge MA, US Michael PACKER - Cambridge MA, US Bernd ZETSCHE - Cambridge MA, US Ian SLAYMAKER - Cambridge MA, US Yi YU - Cambridge MA, US David A. BORN - Cambridge MA, US Seung-Joo LEE - Cambridge MA, US
The present invention features compositions and methods for editing deleterious mutations associated with alpha-1 anti-trypsin (A1AT) deficiency. In particular embodiments, the invention provides methods for correcting mutations in an A1AT polynucleotide using an adenosine deaminase base editor, ABE8, having unprecedented levels of efficiency.
Modified Immune Cells Having Adenosine Deaminase Base Editors For Modifying A Nucleobase In A Target Sequence
- Cambridge MA, US Michael PACKER - Cambridge MA, US Ian SLAYMAKER - Cambridge MA, US Yi YU - Cambridge MA, US Bernd ZETSCHE - Cambridge MA, US David A. BORN - Cambridge MA, US Seung-Joo LEE - Cambridge MA, US Jason M. GEHRKE - Cambridge MA, US
Assignee:
BEAM THERAPEUTICS INC. - Cambridge MA
International Classification:
C12N 15/113 C12N 9/22 C12N 9/78
Abstract:
The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
- Cambridge MA, US Michael PACKER - Cambridge MA, US Francine GREGOIRE - Cambridge MA, US Luis BARRERA - Cambridge MA, US Giuseppe CIARAMELLA - Cambridge MA, US
- Cambridge MA, US Michael PACKER - Cambridge MA, US
Assignee:
Beam Therapeutics Inc. - Cambridge MA
International Classification:
C12N 9/78 C12N 9/22 C12N 15/10
Abstract:
The invention features novel programmable nucleobase editors comprising adenosine deaminase domains and methods of using the same for polynucleotide editing. In some embodiments, programmable nucleobase editors edit a pathogenic mutation associated with a genetic disease.
Calculus of the Urinary System Undescended and Retractile Testicle Urinary Incontinence
Languages:
English Spanish
Description:
Dr. Packer graduated from the Columbia University College of Physicians and Surgeons in 1979. He works in Sewell, NJ and 1 other location and specializes in Urology and Pediatric Urology. Dr. Packer is affiliated with Virtua Voorhees Hospital.
Anxiety Phobic Disorders Disorders of Lipoid Metabolism Fractures, Dislocations, Derangement, and Sprains Skin and Subcutaneous Infections Abdominal Hernia
Languages:
English Spanish
Description:
Dr. Packer graduated from the University of Washington SOM in 1994. He works in Rexburg, ID and specializes in Family Medicine. Dr. Packer is affiliated with Madison Memorial Hospital.
There is no question that at least some insurance companies already use the Internet and social media as part of their underwriting and/or claims handling process, says Michael Packer, attorney with Marshall, Dennehey, Warner, Coleman & Goggin, which represents insurers.